pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immuno-oncology · news · pharmadog
← back to Immuno-oncology
News mentioning Immuno-oncology
47
stories
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 28, 26
Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
fiercebiotech
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 20, 26
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
Aug 20, 26
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
Aug 20, 26
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
fiercebiotech
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 7, 26
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
fiercebiotech
Aug 6, 26
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 15, 26
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
biospace
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
← prev
page 2 of 2
next →